Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): A randomised, double-blind, parallel-group study

The Lancet Respiratory Medicine

Volumn 1, Issue 3, 2013, Pages 199-209

  Wedzicha, Jadwiga A ^a   Decramer, Marc ^b   Ficker, Joachim H ^c,d   Niewoehner, Dennis E ^e   Sandström, Thomas ^f   Taylor, Angel Fowler ^g   D'Andrea, Peter ^g   Arrasate, Christie ^g   Chen, Hungta ^g   Banerji, Donald ^g  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c Paracelsus Medical University Nuremberg   (Germany)

^d KLINIKUM NÜRNBERG   (Germany)

^e UNIVERSITY OF MINNESOTA   (United States)

^f UMEÅ UNIVERSITY   (Sweden)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPYRRONIUM BROMIDE; INDACATEROL; INDACATEROL PLUS GLYCOPYRRONIUM; QVA 149; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE RESPIRATORY FAILURE; ADULT; ARTHRALGIA; ARTICLE; BACKACHE; BACTERIAL INFECTION; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED STUDY; CONTUSION; COUGHING; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DRY POWDER INHALER; DYSPEPSIA; DYSPNEA; FEMALE; FEVER; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HEADACHE; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFLUENZA; INSOMNIA; KIDNEY DISEASE; LOBAR PNEUMONIA; LOWER RESPIRATORY TRACT INFECTION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; NAUSEA; NEOPLASM; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OROPHARYNX PAIN; PAIN; PARALLEL DESIGN; PERIPHERAL EDEMA; PHARYNGITIS; PNEUMONIA; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SMOKING; SPUTUM; THORAX PAIN; THRUSH; TOOTH PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT DISEASE; URINARY TRACT INFECTION; VASCULAR DISEASE; VIRUS INFECTION;

ADMINISTRATION, INHALATION; AGED; BRONCHODILATOR AGENTS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG MONITORING; FEMALE; GLYCOPYRROLATE; HUMANS; INDANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; RESPIRATORY FUNCTION TESTS; RESPIRATORY SYSTEM; SCOPOLAMINE DERIVATIVES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84877131237     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(13)70052-3     Document Type: Article

References (46)

1. Kanner RE, Anthonisen NR, Connett JE Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med 2001, 164:358-364. Lung Health Study Research Group.
2. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002, 57:847-852.
3. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005, 60:925-931.
4. Connors AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996, 154:959-967.
5. Pitta F, Troosters T, Probst VS, et al. Physical activity and hospitalization for exacerbation of COPD. Chest 2006, 129:536-544.
6. Donaldson GC, Wilkinson TM, Hurst JR, Perera WR, Wedzicha JA Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005, 171:446-452.
7. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157:1418-1422.
8. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease Global Initiative for Chronic Obstructive Lung Disease (GOLD), (accessed April 11, 2013). http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf.
9. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005, 143:317-326.
10. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008, 177:19-26. for the INSPIRE Investigators.
11. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011, 364:1093-1103.
12. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-789.
13. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359:1543-1554. for the UPLIFT Study Investigators.
14. Donohue JF, Fogarty C, Lötvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010, 182:155-162.
15. Buhl R, Dunn LJ, Disdier C, et al. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J 2011, 38:797-803.
16. Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010, 65:473-479.
17. D'Urzo A, Ferguson GT, van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res 2011, 12:156.
18. Kerwin E, Hébert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with moderate-to-severe COPD over 52 weeks: the GLOW2 study. Eur Respir J 2012, 40:1106-1114.
19. Jones PW, Donohue JF, Nedelman J, et al. Correlatin changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis. Respir Res 2011, 12:161.
20. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 161:1608-1613.
21. Wilkinson TM, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004, 169:1298-1303.
22. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005, 26:319-338.
23. Jones PW, Quirk FH, Baveystock CM, Littlejohns P A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992, 145:1321-1327.
24. Global Strategy for the Diagnosis, Management and Prevention of COPDManagement and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD)Global Initiative for Chronic Obstructive Lung Disease (GOLD), (accessed April 11, 2013). http://www.goldcopd.org/.
25. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157:1418-1422.
26. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987, 106:196-204.
27. Keene ON, Jones MR, Lane PW, Anderson J Analysis of exacerbation rates in asthma and chronic obstructive pulmonary disease: example from the TRISTAN study. Pharm Stat 2007, 6:89-97.
28. 2010 CG101. Chronic obstructive pulmonary disease. Management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update) National Institute for Health and Clinical Excellence, NICENICE, (accessed April 10, 2013). http://guidance.nice.org.uk/CG101.
29. van den Berge M, Hop WC, van der Molen T, et al. Prediction and course of symptoms and lung function around an exacerbation in chronic obstructive pulmonary disease. Respir Res 2012, 13:44.
30. Donaldson GC, Seemungal TA, Patel IS, et al. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J 2003, 22:931-936.
31. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 363:1128-1138.
32. Suissa S, Dell'aniello S, Ernst P Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012, 67:957-963.
33. Langsetmo L, Platt RW, Ernst P, Bourbeau J Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med 2008, 177:396-401.
34. Andersson F, Borg S, Jansson SA, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002, 96:700-708.
35. Johnson M, Rennard S Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD. Chest 2001, 120:258-270.
36. Wedzicha J, Decramer M, Seemungal T The role of bronchodilator treatment in the prevention of exacerbations of COPD. Eur Respir J 2012, 40:1545-1554.
37. Vogelmeier C, Kardos P, Harari S, et al. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 2008, 102:1511-1520.
38. van Noord JA, Aumann JL, Janssens E, et al. Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms. Respir Med 2010, 104:995-1004.
39. van Noord JA, Buhl R, Laforce C, et al. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax 2010, 65:1086-1091.
40. Spencer S, Calverley PM, Burge PS, Jones PW Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004, 23:698-702.
41. Miravitlles M, Calle M, Alvarez-Gutierrez F, et al. Exacerbations, hospital admissions and impaired health status in chronic obstructive pulmonary disease. Qual Life Res 2006, 15:471-480.
42. Brusse-Keizer M, van der Palen J, van der Valk P, Hendrix R, Kerstjens H Clinical predictors of exacerbation frequency in chronic obstructive pulmonary disease. Clin Respir J 2011, 5:227-234.
43. Nici L, Donner C, Wouters E, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006, 173:1390-1413.
44. Tamura G, Ohta K Adherence to treatment by patients with asthma or COPD: comparison between inhaled drugs and transdermal patch. Respir Med 2007, 101:1895-1902.
45. Toy E, Beaulieu N, McHale J, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med 2011, 105:1435-1441.
46. Breekveldt-Postma NS, Koerselman J, Erkens JA, et al. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir Med 2007, 101:1398-1405.